Search
Bilastine
go.drugbank.com/drugs/DB11591ApprovedBilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Desloratadine
go.drugbank.com/drugs/DB00967ApprovedInvestigationalIt is the active descarboethoxy metabolite of loratidine (a second generation histamine). … Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action.
Lancovutide
go.drugbank.com/drugs/DB05029InvestigationalLancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis. … Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics.
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. … Pegaptanib was granted FDA approval on 17 September 2004.[L17903]
CHGN111
go.drugbank.com/drugs/DB06376ExperimentalNumerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.
Luseogliflozin
go.drugbank.com/drugs/DB12214InvestigationalLuseogliflozin has been used in trials studying the treatment of Diabetes Melltius, Type 2.
Categories: Drugs Used in DiabetesAG-858
go.drugbank.com/drugs/DB05502InvestigationalTumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. … AG-858 (autologous heat-shock protein 70 peptide vaccine) is a recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes.
Eszopiclone
go.drugbank.com/drugs/DB00402ApprovedInvestigationalThis sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004. … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.
Muraglitazar
go.drugbank.com/drugs/DB06510Investigationalin LDL-C levels. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease
PAC-113
go.drugbank.com/drugs/DB05756InvestigationalPAC-113 is targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction. … PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva.